ストックスクリーナーアプリを入手
2.20
7.56%
-0.18
アフターアワーズ：
2.20
前日終値:
$2.38
開ける：
$2.42
24時間の取引高:
155.46K
Relative Volume:
1.15
時価総額：
$52.64M
収益：
-
当期純損益:
$-21.54M
株価収益率:
-2.2213
EPS:
-0.9904
ネットキャッシュフロー:
$-19.60M
1週間 パフォーマンス:
-8.33%
1か月 パフォーマンス:
-25.93%
6か月 パフォーマンス:
-68.12%
1年 パフォーマンス:
-78.70%
1日の値動き範囲:
$2.15
$2.4999
1週間の範囲:
$2.15
$2.79
52週間の値動き範囲:
$1.58
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Compare ACTU vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
2.20 | 56.94M | 0 | -21.54M | -19.60M | -0.9904 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-26 | 開始されました | B. Riley Securities | Buy |
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com India
Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
Actuate Therapeutics Stockholders Elect Directors, Ratify Auditor - TipRanks
Actuate Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com
Actuate Therapeutics, Inc.Common stock (NQ: ACTU - The Chronicle-Journal
Actuate Therapeutics (ACTU) Holds Near Support After Modest UptickCrowd Breakout Signals - Newser
ACTU Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co. - Moomoo
Actuate Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Actuate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Actuate Therapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Actuate Wins FDA Clearance for Oral Elraglusib Trial - TipRanks
Actuate Therapeutics (NASDAQ: ACTU) gets FDA IND ok but flags cash risk - Stock Titan
Actuate Therapeutics Announces FDA Clearance of IND for - GlobeNewswire
Pancreatic cancer drug elraglusib moves to pill form after survival gains - Stock Titan
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Actuate Therapeutics Adds Oncology Veteran Martin Huber to Board as Elraglusib Advances - citybiz
Actuate Therapeutics appoints Martin Huber to board - Investing.com
Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia
Actuate Therapeutics Appoints Dr. Martin Huber as Independent Director to Strengthen Leadership Team - Quiver Quantitative
Cancer drug developer Actuate taps ex-Mersana CEO for board seat - Stock Titan
Actuate Therapeutics, Inc. Announces Appointment of Martin Huber as an Independent Director, Effective May 6, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN
Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat
Actuate Therapeutics announces public offering of common stock - MSN
Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo
HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU) - MarketBeat
H.C. Wainwright reiterates Buy on Actuate Therapeutics stock By Investing.com - Investing.com Canada
Actuate Therapeutics Inc - Reuters
12 Health Care Stocks Moving In Tuesday's After-Market SessionActuate Therapeutics (NASDAQ:ACTU), Celu - Benzinga
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
HC Wainwright Issues Optimistic Estimate for ACTU Earnings - National Today
B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com
Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial doubled one-year survival in study - Stock Titan
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature
ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Actuate Therapeutics Inc (ACTU) 財務データ
収益
当期純利益
現金流量
EPS
Actuate Therapeutics Inc (ACTU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| THOMSON TODD S | Director |
Jan 05 '26 |
Sale |
5.80 |
280,000 |
1,624,000 |
904,795 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):